Santana Yanira, Montejo Angel L, Martín Javier, LLorca Ginés, Bueno Gloria, Blázquez Juan Luis
Department of Psychiatry, Hospital Universitario de Salamanca, 37007 Salamanca, Spain.
University of Salamanca, IBSAL, Nursing School E.U.E.F., 37007 Salamanca, Spain.
J Clin Med. 2019 Jan 23;8(2):133. doi: 10.3390/jcm8020133.
Antidepressant-related sexual dysfunction is a frequent adverse event caused by serotonergic activation that intensely affects quality of life and adherence in depressed patients. The dopamine system has multiple effects promoting sexual behavior, but no studies have been carried out to confirm dopaminergic changes involved in animal models after antidepressant use.
The sexual behavior-related dopaminergic system in the rat was studied by comparing two different antidepressants and placebo for 28 days. The antidepressants used were paroxetine (a serotonergic antidepressant that causes highly frequent sexual dysfunction in humans) and agomelatine (a non-serotonergic antidepressant without associated sexual dysfunction). The tyrosine hydroxylase immunoreactivity (THI) in the substantia nigra pars compacta, the ventral tegmental area, the zona incerta, and the hypothalamic arcuate nucleus, as well as the dopaminergic projections to the striatum, hippocampus, cortex, and median eminence were analyzed.
The THI decreased significantly in the substantia nigra and ventral tegmental area after treatment with paroxetine, and the labeling was reduced drastically in the zona incerta and mediobasal hypothalamus. The immunoreactive axons in the target regions (striatum, cortex, hippocampus, and median eminence) almost disappeared only in the paroxetine-treated rats. Conversely, after treatment with agomelatine, a moderate reduction in immunoreactivity in the substantia nigra was found without appreciable modifications in the ventral tegmental area, zona incerta, and mediobasal hypothalamus. Nevertheless, no sexual or copulatory behavior was observed in any of the experimental or control groups.
Paroxetine but not agomelatine was associated with important decreased activity in dopaminergic areas such as the substantia nigra and ventral tegmental areas that could be associated with sexual performance impairment in humans after antidepressant treatment.
抗抑郁药相关的性功能障碍是由5-羟色胺能激活引起的常见不良事件,严重影响抑郁症患者的生活质量和依从性。多巴胺系统对性行为有多种促进作用,但尚未有研究证实抗抑郁药使用后动物模型中涉及的多巴胺能变化。
通过比较两种不同的抗抑郁药和安慰剂治疗28天,研究大鼠性行为相关的多巴胺能系统。所用的抗抑郁药为帕罗西汀(一种在人类中导致高频性功能障碍的5-羟色胺能抗抑郁药)和阿戈美拉汀(一种无相关性性功能障碍的非5-羟色胺能抗抑郁药)。分析黑质致密部、腹侧被盖区、未定带和下丘脑弓状核中的酪氨酸羟化酶免疫反应性(THI),以及向纹状体、海马、皮质和正中隆起的多巴胺能投射。
帕罗西汀治疗后,黑质和腹侧被盖区的THI显著降低,未定带和下丘脑中间基底部的标记大幅减少。仅在帕罗西汀治疗的大鼠中,目标区域(纹状体、皮质、海马和正中隆起)的免疫反应性轴突几乎消失。相反,阿戈美拉汀治疗后,黑质中的免疫反应性有适度降低,腹侧被盖区、未定带和下丘脑中间基底部无明显改变。然而,在任何实验组或对照组中均未观察到性行为或交配行为。
帕罗西汀而非阿戈美拉汀与黑质和腹侧被盖区等多巴胺能区域的重要活性降低有关,这可能与抗抑郁药治疗后人类的性功能损害有关。